Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2280]

Using Hsp90 inhibitors in the clinic: what have we learned?

Dr Udai Banerji - Institute of Cancer Research, Sutton, United Kingdom

Using Hsp90 inhibitors in the clinic: what have we learned? ( Dr Udai Banerji - Institute of Cancer Research, Sutton, United Kingdom )

Radiogenomic evaluation of tumour response to targeted agents

Dr Ronald Korn - CMO and founder of Imaging Endpoints, Scottsdale, USA

Radiogenomic evaluation of tumour response to targeted agents ( Dr Ronald Korn - CMO and founder of Imaging Endpoints, Scottsdale, USA )

New drugs and targets in haematological malignancies

Dr Renier Brentjens - Memorial Sloan Kettering Cancer Center, New York, USA

New drugs and targets in haematological malignancies ( Dr Renier Brentjens - Memorial Sloan Kettering Cancer Center, New York, USA )

Mutant-specific kinase inhibitors and TAT highlights

Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France

Mutant-specific kinase inhibitors and TAT highlights ( Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France )

Drugging the cancer genome to overcome drug resistance

Prof Paul Workman - Institute of Cancer Research, UK

Drugging the cancer genome to overcome drug resistance ( Prof Paul Workman - Institute of Cancer Research, UK )

Expert commentary on emerging research in genitourinary cancer

Dr Chris Parker - The Royal Marsden Hospital, London, UK

Expert commentary on emerging research in genitourinary cancer ( Dr Chris Parker - The Royal Marsden Hospital, London, UK )

VEGF targeted therapy and chemo an active combination in rapidly progressive...

Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA

VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma ( Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA )

Combination of pazopanib and paclitaxel safe in urothelial cancer

Prof Sandy Srinivas - Stanford University Medical Centre, Stanford, USA

Combination of pazopanib and paclitaxel safe in urothelial cancer ( Prof Sandy Srinivas - Stanford University Medical Centre, Stanford, USA )

Tackling renal cancer with a combination of autologous immunotherapy and...

Prof Robert Figlin - Cedars-Sinai, Los Angeles, USA

Tackling renal cancer with a combination of autologous immunotherapy and sunitinib ( Prof Robert Figlin - Cedars-Sinai, Los Angeles, USA )

ASCO GU 2015: Prostate highlights from day one

Prof Karim Fizazi, Prof Kurt Miller, Dr Maria De Santis, Dr Mark Rubin

ASCO GU 2015: Prostate highlights from day one ( Prof Karim Fizazi, Prof Kurt Miller, Dr Maria De Santis, Dr Mark Rubin )

Challenging results from mTOR inhibitors in metastatic clear cell renal cancer

Prof Thomas Powles - Barts Health, London, UK

Challenging results from mTOR inhibitors in metastatic clear cell renal cancer ( Prof Thomas Powles - Barts Health, London, UK )

Metastatic prostate cancer - Interpreting negative trial results

Prof Stephane Oudard and Prof Noel Clarke

Metastatic prostate cancer - Interpreting negative trial results ( Prof Stephane Oudard and Prof Noel Clarke )

More from ecancer